case | 12 Oct 2021

Setterwalls has assisted CombiGene AB in its licensing agreement with Spark Therapeutics

Responsive image

Setterwalls has, together with the Swiss law firm, Vischer, assisted CombiGene AB (listed on Stockholm Nasdaq First North Growth Market) in entering into an exclusive, global collaboration- and licensing agreement for CombiGene’s CG01 project.

The CG01 project is a gene therapy that aims to treat drug resistant focal epilepsy with Spark Therapeutics, a US-based company within the Roche Group.

  • This field is for validation purposes and should be left unchanged.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.